Suchergebnisse - "Bertulli, Rossella"

PubPharm (5)

1

SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer : results from the OnCovid registry

enthalten in: The Lancet. Oncology | 2023

von Cortellini, A. | Tabernero, J. | Mukherjee, U. | +126

2

Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe : results from the retrospective, multicentre, OnCovid registry study

enthalten in: The Lancet. Oncology | 2022

von Pinato, D. | Aguilar-Company, J. | Ferrante, D. | +147

3

Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection : evidence from the OnCovid retrospective, multicentre registry study

enthalten in: The Lancet. Oncology | 2021

von Pinato, D. | Tabernero, J. | Bower, M. | +130

4

Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS) : an open-label, phase 1b study from the Italian Sarcoma Group

enthalten in: The Lancet. Oncology | 2018

von Grignani, G. | D'Ambrosio, L. | Pignochino, Y. | +21

CommentIn: Lancet Oncol. 2018 Oct;19(10):1269-1270. - PMID 30217674

5

Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment : a non-randomised phase 2 clinical trial

enthalten in: The Lancet. Oncology | 2015

von Grignani, G. | Palmerini, E. | Ferraresi, V. | +16

CommentIn: Lancet Oncol. 2015 Jan;16(1):12-3. - PMID 25638539

1
[1]